Table of Contents
- What is Irinotecan Hydrochloride Trihydrate?
- Treatment Approach for Esophageal Cancer
- How Irinotecan Works
- Dosage and Administration
- Expected Outcomes and Measures
- Potential Side Effects
What is Irinotecan Hydrochloride Trihydrate?
Irinotecan Hydrochloride Trihydrate, often simply referred to as Irinotecan, is a powerful chemotherapy drug used in the treatment of various cancers. In this clinical trial, it is being studied specifically for its effectiveness against esophageal cancer, a serious form of cancer that affects the tube connecting the throat to the stomach[1].
Treatment Approach for Esophageal Cancer
The clinical trial is exploring a comprehensive treatment approach for potentially resectable thoracic esophageal cancer. This means the cancer is located in the chest area of the esophagus and may be removable through surgery. The treatment plan includes:
- Pre-operative chemotherapy: This involves giving chemotherapy drugs before surgery to shrink the tumor.
- Radiotherapy: This includes both external beam radiation and brachytherapy (a type of internal radiation).
- Surgery: After the chemotherapy and radiation, surgery is performed to remove the remaining cancer[1].
This combination approach aims to improve the chances of successfully treating esophageal cancer compared to using surgery alone.
How Irinotecan Works
Irinotecan is used in combination with another chemotherapy drug called Cisplatin. Together, these drugs are expected to be more effective in treating esophageal cancer than older drug combinations. Here’s how they work:
- Targeting cancer cells: Both Irinotecan and Cisplatin are designed to attack and kill cancer cells.
- Radiosensitizing properties: These drugs make cancer cells more sensitive to radiation therapy, potentially improving its effectiveness[1].
- Controlling metastasis: The drug combination is hoped to better control the spread of cancer to other parts of the body (metastasis).
Dosage and Administration
In this clinical trial, Irinotecan is administered as follows:
- Dosage: 65mg/m² (milligrams per square meter of body surface area)
- Schedule: Given during weeks 1-2, 4-5, and 7-8 of the treatment cycle[1]
This dosage and schedule are designed to maximize the drug’s effectiveness while managing potential side effects.
Expected Outcomes and Measures
The clinical trial is looking at several important outcomes to determine how well Irinotecan works for esophageal cancer:
- Pathological complete response: This is the main outcome being measured. It refers to the absence of any detectable cancer cells after treatment[1].
- Disease-free survival: How long patients live without any signs of cancer returning.
- Overall survival: How long patients live after starting treatment.
- Quality of life: Measured using a specific questionnaire called FACT-E.
- Clinical complete response rate: How many patients show no signs of cancer after treatment, based on medical examinations and scans.
Potential Side Effects
While the specific side effects of Irinotecan in this trial are not detailed, the study is monitoring for both acute (short-term) and late (long-term) toxicities[1]. Common side effects of chemotherapy drugs like Irinotecan may include:
- Nausea and vomiting
- Fatigue
- Hair loss
- Increased risk of infections
It’s important to note that not everyone experiences the same side effects, and your healthcare team will work to manage any that do occur.
